Novartis’ Lp(a) drug misses Phase 3 endpoint
Novartis’ pelacarsen failed to reduce cardiovascular events in the first Phase 3 outcomes trial of an Lp(a)-lowering drug, despite successfully lowering the genetically driven cardiovascular risk factor.
About Joachim Eeckhout
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 117 entries already.
Entries by Joachim Eeckhout
Transgene cancer vaccine keeps patients relapse-free for three years
French biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a randomized Phase 1 trial remained disease-free after three years, while three of 16 patients in the control arm relapsed.
GSK bets $1.3B on KRAS-EGFR conjugate from HUTCHMED
GSK has licensed ex-China rights to HUTCHMED’s HMPL-A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to $1.295 billion (€1.12 billion). The preclinical asset is expected to enter the clinic this year.
Novartis breaks BTK losing streak in multiple sclerosis
Novartis’ remibrutinib has beaten teriflunomide in two Phase 3 trials in relapsing multiple sclerosis (MS), adding another important clinical win for a class of BTK inhibitors that has endured several high-profile failures in autoimmune disease.
Roche reloads B-cell strategy with $1.53B Simcere deal
Roche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a deal potentially worth $1.53 billion (€1.32 billion).
Adaptyv raises $40M for AI-run wet labs
Swiss biotech Adaptyv has raised a $40 million (€34.5 million) Series A to expand its automated protein-testing labs, betting that wet-lab capacity will become a critical bottleneck as AI models generate ever more biological designs.
Molecular surgery: How Europe can lead the world
KJ Muldoon’s survival was not just a medical breakthrough. It was a glimpse of a new category of medicine, in which a genetic error can be corrected with the precision of an operation rather than developed as a conventional drug. Can Europe build the system that turns one extraordinary rescue into a repeatable model?
BioNTech cancer vaccine trial halted after survival imbalance
BioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine autogene cevumeran in colorectal cancer after more deaths occurred in the vaccine arm than among patients under observation. The setback comes just days after rival Moderna scored the first Phase 3 success for an individualized mRNA cancer therapy — albeit in combination with a checkpoint inhibitor.
Revealis enters cancer vaccine race with TEIPP strategy
Dutch startup Revealis Biotherapeutics has launched to develop a new generation of cancer vaccines targeting tumor cells that have become difficult for T cells to recognize, building on an academic program that has already reached patients.
Apollo vaccine triggers broad rhinovirus immunity in Phase 1
UK biotech Apollo Therapeutics has reported early Phase 1 data showing that one dose of its experimental rhinovirus vaccine, APL-10456, induced immune responses recognizing all three rhinovirus species in healthy adults.